Published in Diabetes on October 01, 1990
Perinatal exposure to bisphenol a alters early adipogenesis in the rat. Environ Health Perspect (2009) 1.98
Lipid and lipoprotein profiles in youth with and without type 1 diabetes: the SEARCH for Diabetes in Youth case-control study. Diabetes Care (2008) 1.51
Insulin resistance in type 1 diabetes: what is 'double diabetes' and what are the risks? Diabetologia (2013) 1.26
Quantification of human serum paraoxonase by enzyme-linked immunoassay: population differences in protein concentrations. Biochem J (1994) 1.15
Identification of membrane-bound CR1 (CD35) in human urine: evidence for its release by glomerular podocytes. J Exp Med (1994) 1.08
HDLs protect pancreatic β-cells against ER stress by restoring protein folding and trafficking. Diabetes (2012) 0.93
Atherosclerosis severity is not affected by a deficiency in IL-33/ST2 signaling. Immun Inflamm Dis (2015) 0.78
The effect of the gastrointestinal lipase inhibitor, orlistat, on serum lipids and lipoproteins in patients with primary hyperlipidaemia. Eur J Clin Pharmacol (1994) 2.04
Identification of a distinct human high-density lipoprotein subspecies defined by a lipoprotein-associated protein, K-45. Identity of K-45 with paraoxonase. Eur J Biochem (1993) 1.57
Characterization of subpopulations of lipoprotein particles isolated from human cerebrospinal fluid. Biochim Biophys Acta (1995) 1.16
Quantification of human serum paraoxonase by enzyme-linked immunoassay: population differences in protein concentrations. Biochem J (1994) 1.15
Apolipoprotein B metabolism in homozygous familial hypercholesterolemia. J Lipid Res (1989) 1.09
Asymptomatic bacteriuria in diabetes mellitus. N Engl J Med (1967) 1.05
Low density lipoprotein causes general cellular activation with increased phosphatidylinositol turnover and lipoprotein catabolism. Proc Natl Acad Sci U S A (1988) 1.00
Relationship between plasma insulin levels and high density lipoprotein cholesterol levels in healthy men. Diabetologia (1981) 0.95
Characterization of a human high density lipoprotein-associated protein, NA1/NA2. Identity with SP-40,40, an inhibitor of complement-mediated cytolysis. Arterioscler Thromb (1991) 0.94
Protein heterogeneity of lipoprotein particles containing apolipoprotein A-I without apolipoprotein A-II and apolipoprotein A-I with apolipoprotein A-II isolated from human plasma. J Lipid Res (1988) 0.90
Treatment of hyperlipoproteinemia (HLP) type II A with a new phenoxy-isobuturic acid derivative, procetofen. Int J Clin Pharmacol Biopharm (1979) 0.85
[Dyslipidemia in the diabetic patient. Recommendations of ALFEDIAM (French Language Association for the Study of Diabetes and Metabolic Diseases)]. Diabete Metab (1995) 0.85
Lipoprotein (a) and vascular disease in diabetic patients. Diabetologia (1995) 0.83
Immunoaffinity fractionation of high-density lipoprotein subclasses 2 and 3 using anti-apolipoprotein A-I and A-II immunosorbent gels. Biochim Biophys Acta (1989) 0.82
Distribution of apolipoprotein E between free and A-II complexed forms in very-low- and high-density lipoproteins: functional implications. Biochim Biophys Acta (1991) 0.81
HDL lipids in close relatives of coronary heart disease patients. Environmental and genetic influences. Atherosclerosis (1979) 0.81
Liver glycerokinase deficiency in man with hyperglycerolaemia and hypertriglyceridaemia. Eur J Clin Invest (1984) 0.81
HDL particle associated proteins in plasma and cerebrospinal fluid: identification and partial sequencing. Appl Theor Electrophor (1988) 0.81
Iron excess, early glucose intolerance and impaired insulin secretion in idiopathic haemochromatosis. Eur J Clin Invest (1973) 0.81
Immunofractionation of high density lipoprotein subclasses 2 and 3. Similarities and differences of fractions isolated from male and female populations. Atherosclerosis (1990) 0.80
Metabolic effects of dietary fiber from dehulled soybeans in humans. Am J Clin Nutr (1983) 0.80
[Apoprotein E (apo E) phenotype and serum lipids in diabetics]. Schweiz Med Wochenschr (1987) 0.79
Phenotyping is an accurate means of analysing the principal apolipoprotein E isoforms. Clin Chim Acta (1994) 0.78
The distribution profiles of very low density and low density lipoproteins in poorly-controlled male, type 2 (non-insulin-dependent) diabetic patients. Diabetologia (1991) 0.78
Postprandial lipemia differentially influences high density lipoprotein subpopulations LpAI and LpAI,AII. J Lipid Res (1994) 0.78
High density lipoprotein cholesterol in male relatives of patients with coronary heart disease. Atherosclerosis (1979) 0.78
Apolipoprotein E polymorphism as a risk factor for vascular disease in diabetic patients. Diabetes Care (1995) 0.78
Apoprotein D in a healthy, male population and in male myocardial infarction patients and their male, first-degree relatives. Atherosclerosis (1986) 0.77
HDL and coronary heart disease: a familial trend. Adv Exp Med Biol (1987) 0.77
Underexpression of the apolipoprotein E4 isoform in an Italian population. Arterioscler Thromb (1993) 0.77
Factors influencing the low density lipoprotein profile in type 2 diabetic patients. Diabet Med (1995) 0.77
Acquired (secondary) forms of hypertriglyceridemia. Am J Cardiol (1991) 0.77
Decreased HDL cholesterol in prepubertal and pubertal children of CHD patients. Atherosclerosis (1980) 0.76
HDL cholesterol levels in patients with myocardial infarction and their families. Atherosclerosis (1986) 0.76
Gender differences in a type 2 (non-insulin-dependent) diabetic population with respect to apolipoprotein E phenotype frequencies. Diabetologia (1993) 0.76
Effects of ocular carteolol and timolol on plasma high-density lipoprotein cholesterol level. Am J Ophthalmol (1994) 0.75
Marked changes of lipid levels during puberty in a patient with lipoprotein lipase deficiency. Eur J Pediatr (1997) 0.75
[Hypercholesteremia: a problem of daily practice]. Rev Med Suisse Romande (1968) 0.75
[Diet in the treatment of hyperlipidaemia (author's transl)]. Ther Umsch (1980) 0.75
[The development of an extensive dissecting aneurysm of the aorta]. Rev Med Suisse Romande (1965) 0.75
[The clinical importance of cardiovascular risk factors]. Schweiz Rundsch Med Prax (1992) 0.75
Early capillary changes in diabetes mellitus. Acta Diabetol Lat (1971) 0.75
Topical timolol maleate might adversely affect serum lipoproteins. Int Ophthalmol (1993) 0.75
[High-density lipoproteins in children with coronary diseases]. Helv Paediatr Acta (1981) 0.75
The influence of metabolic control on very low density lipoprotein composition in hypertriglyceridemic type II diabetics. A study using heparin-sepharose chromatography. Metabolism (1988) 0.75
Clofibrate, nephrotic syndrome, and histological changes in muscle. Lancet (1973) 0.75
[Hyperlipemia and diabetes]. Schweiz Med Wochenschr (1976) 0.75
Apparent lack of influence of the genetic drug oxidation status on plasma cholesterol concentration in man. Pharmacol Res Commun (1984) 0.75
[Dyslipidemias and diabetes mellitus]. Journ Annu Diabetol Hotel Dieu (1989) 0.75
Preparative isoelectrofocusing and high resolution 2-dimensional gel electrophoresis for concentration and purification of proteins. Appl Theor Electrophor (1991) 0.75
Geneva study on the precursors of atherosclerosis: first results. Soz Praventivmed (1979) 0.75
Lipoprotein complexes in human cerebrospinal fluid. Schweiz Arch Neurol Psychiatr (1993) 0.75
[Comparison of 2 cholesterol synthesis inhibitors (simvastatin and pravastatin)]. Schweiz Med Wochenschr (1993) 0.75
[Coronary insufficiency, hyperlipemia and diabetes]. Journ Annu Diabetol Hotel Dieu (1976) 0.75
High density lipoprotein (HDL) subfractions in cardiovascular patients with low levels of HDL-cholesterol. Influence of hypertriglyceridaemia on subfraction concentration and composition. Atherosclerosis (1988) 0.75
[Low HDL cholesterol in close relatives and patients with myocardial infarct]. Schweiz Med Wochenschr (1978) 0.75
Actin stress fiber content of regenerated endothelial cells correlates with intramural retention of intermediate plus low density lipoproteins in rat aorta after balloon injury. Atherosclerosis (1989) 0.75
[Treatment of systemic lupus erythematosus with antimetabolites. Relations between the clinical course and immunological reactions]. Helv Med Acta (1967) 0.75
[Remnant disease associated with apoprotein E1; clinical importance of apoprotein E (apo E) phenotypes]. Schweiz Med Wochenschr (1989) 0.75
Epitope expression in purified and lipid-bound forms of human apoprotein A-I. Adv Exp Med Biol (1987) 0.75
[Treatment of systemic lupus erythematosus with antimetabolites. Relations between the clinical course and immunological reactions]. Helv Med Acta Suppl (1967) 0.75
[Diagnosis and treatment of hyperlipoproteinemias]. Schweiz Med Wochenschr (1972) 0.75
Immunological confirmation of the presence of NA1/NA2 (cytolysis inhibitor) in cerebrospinal fluid. Schweiz Arch Neurol Psychiatr (1991) 0.75
[Serum lipoproteins in family members of myocardial infarct victims]. Soz Praventivmed (1978) 0.75
[Clinical study on the relationship between diabetes, hyperlipoproteinemia and atheromatosis]. Schweiz Med Wochenschr (1973) 0.75
[Teaching and Treatment Unit in the Division of Diabetology (Geneva)]. Rev Med Suisse Romande (1980) 0.75
[Coronary atherosclerosis and serum lipoproteins]. Schweiz Med Wochenschr (1979) 0.75
[Classification of hyperlipoproteinemia in the light of advances in pathogenetic studies]. Pol Tyg Lek (1985) 0.75
A novel high-density lipoprotein particle and associated protein in rat plasma. Biochim Biophys Acta (1990) 0.75
[Relation between HDL cholesterol and fasting glycemia in a normal population and a diabetic group]. Schweiz Med Wochenschr (1984) 0.75
[Effects of fenofibrate in four types of hyperlipoproteinaemia and on apoproteins A and B in type IIa HLP (author's transl)]. Nouv Presse Med (1980) 0.75
[Influence of hormonal contraception on serum lipoproteins]. Schweiz Med Wochenschr (1978) 0.75
[Cholesterol and triglycerides of serum lipoproteins isolated by means of ultracentrifugation. Correlation with arteriosclerosis]. Schweiz Med Wochenschr (1974) 0.75
[Dietary treatment of the hyperlipidemias]. Ther Umsch (1986) 0.75
[Procetofen in the treatment of hyperlipoproteinaemias (author's transl)]. Schweiz Rundsch Med Prax (1980) 0.75
[The general practitioner confronted with hypercholesteremia]. Schweiz Rundsch Med Prax (1970) 0.75
[Drug therapy of hyperlipemia. Role of drugs at the disposition of general practitioners]. Ther Umsch (1970) 0.75
[Drug therapy of hyperlipoproteinemias]. Ther Umsch (1980) 0.75
Treatment of systemic lupus erythematosus (SLE) with immunosuppressive drugs 1: An analysis of immunologic data. Helv Med Acta (1967) 0.75
[HDL-cholesterol and family incidence of coronary disease in the Genevan population]. Schweiz Med Wochenschr (1983) 0.75
[Diabetic microangiopathy, early or late manifestation of the disease? Electron microscopy study of muscular capillaries]. Helv Med Acta Suppl (1970) 0.75
[Molecular pathophysiology of familial hypercholesterolemia]. Pol Tyg Lek (1985) 0.75
[Dyslipidemias and atherosclerosis. Treatment strategy]. Schweiz Rundsch Med Prax (1986) 0.75
Diabetic retinopathy: study of the action of O-betahydroxyethyl-rutosides (HR) by retinal fluoresceinography. Diabetologia (1970) 0.75
Capillary basement membrane thickness in early diabetes. Adv Metab Disord (1973) 0.75
[Reversible acquired acanthocytosis and hemolytic anemia associated with hypobetalipoproteinemia in a chronic alcoholic]. Schweiz Med Wochenschr (1983) 0.75
[Effect of renal insufficiency on diabetes mellitus]. Rev Med Suisse Romande (1979) 0.75
[Diabetic retinopathy: study on the action of l'o-beta-hydroxyethylrutoside for retinal fluoresceinography]. Helv Med Acta Suppl (1969) 0.75
[Lipoprotein metabolism and atherosclerosis]. Schweiz Rundsch Med Prax (1988) 0.75
[Study of glucose tolerance and insulin secretion (IRI) in familial hemochromatosis]. Helv Med Acta (1972) 0.75
[Why change the fat content of diabetic diets?]. Rev Med Suisse Romande (1973) 0.75
A non-competitive enzyme-linked immunosorbent assay for measuring human plasma apolipoprotein B levels. Clin Chim Acta (1985) 0.75
[Plasma lipoproteins. Influence of heredity and external factors in the genesis of dyslipidemias]. Rev Med Suisse Romande (1980) 0.75
[Vascular complications of diabetes]. Ther Umsch (1967) 0.75
[Dyslipidemia in diabetes mellitus: significance, diagnosis and treatment]. Schweiz Rundsch Med Prax (1990) 0.75
[Factors influencing the rate of elimination of injected fat emulsions (Intralipid) in healthy subjects and in patients with coronary disease]. Schweiz Med Wochenschr (1976) 0.75
[Dietary lipids and serum lipids in adolescents, based on the Geneva study of the precursors of atherosclerosis]. Soz Praventivmed (1984) 0.75
[Prediabetes and early diabetes]. Pol Tyg Lek (1966) 0.75
Interference of dimethyl alpha-(dimethoxyphosphinyl) p-chlorobenzyl phosphate (SR-202) in thyroid hormone metabolism: evidence of inhibition of monodeiodination. J Endocrinol (1987) 0.75